Galectin Therapeutics (GALT) Convertible Debt (2021 - 2026)

Galectin Therapeutics has reported Convertible Debt for 6 years, with the latest figure at $32.9 million in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt rose 204.06% year-over-year to $32.9 million; the trailing twelve-month figure through Mar 2026 stood at $32.9 million (up 204.06% YoY), and the FY2025 full-year result was $32.7 million, up 204.69% from the prior year.
• Convertible Debt for Q1 2026 stood at $32.9 million, up from $32.7 million in the prior quarter.
• The five-year high for Convertible Debt was $32.9 million in Q1 2026, with the low at $10.7 million in Q4 2024.
• Average Convertible Debt over 5 years is $27.7 million, with a median of $30.3 million recorded in 2023.
• Year-over-year, Convertible Debt soared 205.96% in 2022 and sank 65.28% in 2025.
• Tracing GALT's Convertible Debt over 5 years: stood at $30.0 million in 2022, then increased by 3.13% to $30.9 million in 2023, then plunged by 65.27% to $10.7 million in 2024, then jumped by 204.69% to $32.7 million in 2025, then grew by 0.54% to $32.9 million in 2026.
• The last three Convertible Debt figures came in at $32.9 million (Q1 2026), $32.7 million (Q4 2025), and $32.3 million (Q2 2025), per Business Quant data.

Peer Comparison